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Simple Summary: One of the significant issues of the anti-cancer effects of phytochemicals, bioactive
compounds from foods, and other plants, is that the effective dosages of the phytochemicals are too
high to be obtained by oral intake, particularly by food intake. The current study aimed to assess if
the combination of two phytochemicals, luteolin (LUT) and curcumin (CUR), at low dosages where
LUT or CUR alone has no significant effect, synergistically exerts anti-colon cancer. Our results
show that combined LUT and CUR synergistically suppressed colon cancer in cultured cells and
cell-derived xenograft mice, which may be associated with two possible molecular pathways. This
study provides a practical approach to treating or preventing colon cancer in humans by consuming
foods having high levels of luteolin and curcumin.
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Abstract: This study aimed to select a combination of curcumin and luteolin, two phytochemicals
from food, at lower concentrations with a higher inhibitory effect on colon cancer growth and
investigate possible molecular mechanisms of this anti-colon cancer effect. By pairwise combination
screening, we identified that the combination of curcumin (CUR) at 15 µM and luteolin (LUT) at
30 µM (C15L30) synergistically suppressed the proliferation of human colon cancer CL-188 cells,
but the individual chemicals had a little inhibitory effect at the selected concentrations. This result
was also confirmed in other colon cancer DLD-1cells, suggesting that this synergistic inhibitory
effect of C15L30 applies to different colon cancer cells. The combination C15L30 synergistically
suppressed the wound closure (wound healing assay) in CL-188 cells. We also found that the
combination of CUR and LUT (at 20 mg/kg/day and 10 mg/kg/day, respectively, IP injection,
5 days for 2 weeks) synergistically suppressed tumor growth in CL-188 cell-derived xenograft mice.
Western blot results showed that protein levels of Notch1 and TGF-β were synergistically reduced by
the combination, both in CL-188 cells and xenograft tumors. Tumor pathological analysis revealed
that combined CUR and LUT synergistically increased necrosis, but the individual treatment with
CUR and LUT had no significant effect on tumor necrosis. Therefore, combined curcumin and
luteolin synergically inhibit colon cancer development by suppressing cell proliferation, necrosis, and
migration associated with Notch1 and TGF-β pathways. This study provides evidence that colon
cancer may be prevented/treated by consuming foods having high levels of luteolin and curcumin
in humans.
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1. Introduction
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More than 290 different phytochemicals from fruits, vegetables, nuts, and olive oil
are believed to be the primary reason why the Mediterranean diet can reduce the rates of
various chronic diseases, including cancer [1,2]. However, the intake of each phytochemical
from the Mediterranean diet is much lower than the amount used in cellular and animal
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studies [3]. One of the explanations is that multiple phytochemicals at very low levels from
the Mediterranean diet exert synergistic effects. Indeed, there is a vast gap between the
range of concentrations of phytochemicals typically used in cell culture models (at µM
or higher) and the levels in the bloodstream (usually at nM) following consumption of
typical doses in foods and supplements [4,5]. Moreover, it is impossible for humans to
take the amount of the food to reach the required circulating levels of the phytochemical
calculated from the results of studies using animals or cells (for instance, one person needs
25 kg of red wine to reach similar effects in mice) [6]. On the other hand, increasing
studies show that combinations of a couple of phytochemicals synergistically improve
osteoporosis [7], suppress obesity [8], and inhibit breast cancer [9]. Therefore, combining
multiple phytochemicals may be a practical approach to combat cancer.
Curcumin (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, CUR),
is a bioactive compound from Curcuma longa L (turmeric), a common cooking dye and
traditional medical plant. Luteolin (3’,4’,5,7-tetrahydroxyflavone, LUT) is a flavonoid in
many commonly consumed vegetables, including thyme, Chinese celery, radicchio, and
peppers [10]. Individual curcumin [11–13] and luteolin [14–16] are well-known anti-cancer
reagents. However, the half-maximal inhibitory concentration (IC50) of individual LUT
and CUR in cancer cells is 50 µM [17,18] and 4–50 µM [19,20], respectively. These high
concentrations are not physiologically achievable where the highest plasma concentration of
LUT, CUR, and its metabolites transiently reach 15 µM [21] and 0.05 µM [22], respectively.
One of our approaches to narrow the concentration gap between in vitro studies and human
studies is to combine two phytochemicals to synergistically inhibit cancer, while the individual phytochemicals do not have an anti-cancer effect at the selected dosages. Indeed, the
combination of LUT and CUR synergistically inhibited breast cancer both in cultured cells
and xenograft mice (separate manuscript).
In the present study, we screened phytochemicals to select combinations exerting a
synergistic inhibitory effect on colon cancer using a cell proliferation assay. We identified a
novel combination of LUT and CUR synergistically constrains colon cancer cell proliferation
in CL-188 cells and DLD-1 cells and tumor growth in CL-188 cells-derived xenograft mice.
At the same time, the individual LUT and CUR do not have this anti-cancer effect at the
selective dosages both in vitro and in vivo. This synergistic anti-colon cancer effect by this
combination involves regulating the Notch1 and transforming growth factor- beta (TGF-β)
pathways as well as inducing necrosis both in cells and tumors. These results suggest that
the combination of LUT and CUR is an efficient approach to treating colon cancer.
2. Materials and Methods
2.1. Cell Culture and Treatment Reagents
The colon cancer cell line CL-188 (LS174T) and DLD-1 used in this study were obtained
from the American Type Culture Collection (ATCC). The CL-188 cells were maintained
in Minimum Essential Media (MEM), and DLD-1 cells were maintained in Roswell Park
Memorial Institute medium (RPMI 1640, 11875093, Thermo Fisher medium, Waltham, MA,
USA). Media were supplemented with 10% fetal bovine serum (FBS), and 1% Penicillin
(100 U/mL) and streptomycin (100 mg/mL) as an antibiotic source. The cells were incubated in an atmosphere of 5% CO2 at 37 ◦ C. To evaluate the effect of combined curcumin
and luteolin on cell proliferation of CL-188 and DLD-1 cell lines, the medium was switched
to phenol-red-free medium, supplemented with 10% FBS and 1% penicillin/streptomycin.
Phytochemicals (curcumin and luteolin) used in this study were purchased from Sigma
Aldrich (St. Louis, MO, USA). Chemicals were dissolved in DMSO (Sigma, St. Louis, MO,
USA. Cat#: 67-68-5) at 100 mM stock solution and diluted to the concentrations to be used
in cell culture treatments.
2.2. Cell Proliferation Assay
CL-188 cells were seeded in a 12-well plate (6.4 × 104 cells/well) in phenol-red-free
medium essential medium with 10% FBS and 1% penicillin/streptomycin, and DLD-1 cells
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were in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. After
overnight incubation, cells were treated with various concentrations of CUR and LUT or
a combination of both (for instance, DMSO, LUT 30 µM, CUR 10 µM, CUR 10 µM + LUT
30 µM, CUR 15 µM, CUR 15 µM, and LUT 30 µM). The plate was incubated at 37 ◦ C for
72 h. Images were photographed with the microscope; the cell proliferation assay was
performed using the MTT vybrant assay kit according to the manufacturer’s instructions.
In brief, the medium was aspirated from each well and replaced with 200 µL of fresh
medium. Then, 50 µL of PBS-MTT was added to each well, after which the plates were
incubated at 37 ◦ C for 2 h. The SDS-HCl solution was added to each well, followed by
incubation at 37 ◦ C for 4 h. Absorbance was read at 570 nm using the synergy hybrid plate
reader (BioTek Instruments Inc., Winooski, VT, USA. Part # 8041000). All experiments were
separately repeated 5 times.
2.3. Pairwise Combinations Screening
Individual phytochemical was used for pairwise screening using a non-constant concentration of phytochemicals in a ratio 1:1 to achieve a pairwise combination matrix. Cells
were seeded at 6.4 × 104 cells per well in a 24-well plate, 64 wells were used each time with
64 different combinations of 8 concentrations of CUR (0, 1, 5, 8, 10, 12, 15, and 20 µM) and
8 concentrations of LUT (0, 1, 5, 10, 15, 20, 25, and 30 µM) to determine the optimum dose
required to inhibit cell growth. DMSO concentration was normalized for each well. After
72 h of treatment, cell viability was measured using the MTT vibrant assay kit according
to the manufacturer’s instructions. Experiments for the cell line were performed at least
4 times, and each combination has two replicates for each independent experiment. Growth
rate inhibition (GRI) was determined, and the mean values of GRI for each combination
treatment were displayed as a combination matrix plot. A combination index (CI) plot was
used to evaluate the synergistic effect of combination pairs. CI = D1/(Dχ)1 + D2/(Dχ)2 > 1
indicates an antagonistic effect, CI = 1, indicates an additive effect, CI < 1 indicates synergistic effect. Where (Dχ)1 and (Dχ)2 represented concentrations of each drug alone to exert
χ% effect, while (D)1 and (D)2 were concentrations of drugs in combination to elicit the
same effect (CI plot or Chou–Talalay plot [23].The optimized doses of combination pair
with high effect levels (Fa > 0.7) and low CI (<0.6) values were used for further studies.
2.4. Wound-Healing Assay
A wound-healing assay was used to assess changes in the migratory ability of cells as
previously described [24]. The cells were seeded in 6-well plates in the medium containing
10% FBS and 1% P/S. Cells were allowed to grow until about 80% confluency as a monolayer.
Linear wounds were made with a P20 pipette tip in each monolayer well. The cells were
starved with serum-free medium overnight and incubated with 10 µg/mL mitomycin
C for 2 h before the scratch assay, which inhibited mitosis of the cells and allowed us to
distinguish migration from proliferation as reported [25]. The wells were then treated with
various concentrations of curcumin and luteolin or a combination of both for 72 h (DMSO,
LUT 30 µM, CUR 10 µM, CUR 10 µM + LUT 30 µM, CUR 15 µM, CUR 15 Mm + LUT 30 µM).
The plates were returned to the incubator. Images of scratch were taken at 4× magnification
after 0 h, 24 h, and 72 h. The extent of migration of each well was analyzed with ImageJ to
calculate the area of the wound closed and expressed as a percentage of DMSO [24].
2.5. Xenograft Model Establishment and Treatment
Nine-week-old male nude BALB/c mice homozygous for Foxn (Cat#: 007850) were
purchased from Jackson Laboratory (Bar Harbor, Maine). Mice were housed in an environmentally controlled (23 ± 2 ◦ C; 12 h light/dark cycle) animal facility and provided free
access to the Teklad global rodent chow diet (Harlen Indianapolis, Indiana).
CL-188 cells were maintained in MEM in T-75 flasks to reach 80% confluency. Cells
were harvested in Hanks’ Balanced Salt Solution (HBSS, Corning cello, cat#: 20-023-CV)
mixed with Matrigel (Corning, Cat#: 356234) (ratio 1:1). Then, 100 µL of cell mixture
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containing 2 × 106 CL-188 cells was injected subcutaneously into the flank of the hind leg
of each mouse. The tumors were measured using a digital caliper every 2 days throughout
the experiment. Tumor volume was calculated using the formula π/6×L×W×H. Mice
with similar body weight and tumor volume were assigned to the same treatment group.
After 10 days of inoculation, mice with tumor volume averaging 200 mm3 in each group as
described [26].
CUR and LUT (MilliporeSigma, Burlington, MA, USA) were dissolved in a vehicle
containing 5% DMSO, 5% Tween20, and 90% PBS v/v%. Mice were assigned into one of
four (4) groups to be treated with Vehicle, LUT 10 mg/kg body weight, CUR 20 mg/kg body
weight, and a combination of LUT 10 mg/kg body weight + CUR 20 mg/kg body weight
with a total of 9 mice per group. Then, 0.1 mL of chemicals were injected intraperitoneally in
mice every 5 days, allowing 2 days of rest for 2 weeks. The experiment was terminated after
2 weeks, as mice in the vehicle group developed tumors with a volume of approximately
3000 mm3 . Mice were euthanized as per the American Veterinary Clinical Affiliation
(AVMA) guidelines, and tumors were excised, weighed, and stored for further analysis.
Other tissues collected include the liver, serum, and colon. The maximum tumor size
permitted by the Institutional Animal Care and Use Committee (IACUC) of 3000 mm3 .
Animal experiments were approved by the IACUC at Tennessee State University (Nashville,
TN, USA), protocol No. 16-11-636, dated 6 March 2018.
2.6. Western Blot
For cells, harvested cells were lysed in mammalian protein extraction buffer (Cat #:
78501, Thermo-scientific, Waltham, MA, USA. 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1%
sodium deoxycholate, 0.1% SDS) and sonicated for 15 s (5 s thrice) on the ice at intervals.
After centrifuging at 12.7 RPM for 5 min at 4 ◦ C, the supernatant was removed, and
protein concentration was measured using the Pierce BCA protein assay kit (Thermo
Scientific, Waltham, MA, USA, Cat #: 23225). For tumors, the frozen mice tumors were
cut, weighed (20–30 mg), and placed in 400 µL of mammalian protein extraction buffer.
The tissue was cut into very tiny pieces and homogenized using a tissue homogenizer
(Biospec Products Inc., Bartlesville, OK, USA. Model 985370) at a level of 20,000 RPM
for 5 s thrice on ice at intervals. Tumor lysate was centrifuged at 12.7 RPM for 5 min at
4 ◦ C (Thermo scientific., Waltham, MA, USA 75002446), and the medium part was used to
measure protein concentration using the Pierce BCA protein assay kit. Based on the protein
centration of the sample, each total protein was added with an appropriate sample buffer
and heated at 95 ◦ C for 5 min. Total protein concentration was loaded on the SDS-PAGE gel
and transferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Piscataway, NJ,
USA). The membranes were blocked with 5% non-fat dry milk at room temperature for 1 h.
Antibodies against NOTCH1 (D1E11), GAPDH (D16H11), and TGF-β (56E4) (purchased
from Cell Signaling Technology, Danvers, MA, USA) were used for immunoblotting, all
at a dilution factor of 1:1000. Membranes were incubated with secondary antibodies at
room temperature for 1 h, and intensities of X-ray films were quantified using the ImageJ
software. The NOTCH1 and TGF- β proteins in the experiment were normalized with
GAPDH as an internal control to confirm that protein loading is equal across the gel as we
described [9]. Please see original WB images in Supplementary Figures S1 and S2.
2.7. Histological Analysis
Tumors excised from mice were fixed in 10% formalin. The tissues were processed
by dehydrating, clearing, infiltration, embedding, and sectioning. These sections were
then subjected to H&E staining [27]. Photomicrographs of representative regions of each
tumor were captured using an Olympus BX41 microscope. An Olympus UC90 microscopemounted camera and Olympus cellSens Standard 1.18 photomicrograph capturing software.
Images were taken at 20× magnification and imported into the Java image processing software, ImageJ. Images were converted to 8bit in ImageJ and evaluated using the thresholding
tool as described in the ImageJ user manual. Threshold levels were selected to measure
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all pixels in the selected image representing all tissue uptaking hematoxylin and eosin
stain. A second threshold level was set to measure all pixels reaching an intensity threshold
that represented a viable (non-necrotic) tumor. The difference in total pixels minus those
whose threshold level matched that of the viable tumor was interpreted as necrosis, and a
percentage was calculated.
2.8. Statistical Analysis
Experiments were repeated at least thrice for in vitro studies. Data were analyzed with
one-way ANOVA and expressed as mean ± standard error. Paired T-tests were used to
differentiate between mean where different. A significant difference was set at p < 0.05 (*),
p < 0.01 (**), and p < 0.001 (***).
3. Results
3.1. Combination of Luteolin and Curcumin Synergistically Inhibited Human Colon Cancer Cell
Proliferation in CL-188 Cells and DLD-1 Cells
Based on our recent screening of 20 phytochemicals, the combination of curcumin and
luteolin synergistically inhibited breast cancer cell proliferation (separate manuscript). In
the present study, we would like to investigate if the combination of curcumin and luteolin
also synergistically inhibits colon cancer cell proliferation. Firstly, we conducted a time
course (24 h, 48 h, and 72 h) to determine the optimum time with the best inhibitory effects
of the combination in CL-188 cells and DLD-1 cells. We found that 72 h treatment has the
most inhibitory effects of the combination in the two cell lines (Figure 1A). Next, eight
concentrations of curcumin and luteolin were selected to generate a dose-response curve in
CL-188 cells. The IC50 for luteolin and curcumin were 27.3 µM and 13.4 µM, respectively.
Pairwise combination screening for the concentrations of luteolin (0, 1, 5, 10, 15, 20, 25, and
30 µM) and curcumin (0, 1, 5, 8, 10, 12, 15, and 20 µM) in 8 × 8 dose-response matrix was
conducted to select the best combination. This combination should have a low combination
index (CI) and has a high inhibitory effect, but the individual chemical had few inhibitory
effects at the chosen concentrations. Figure 1B shows the heat map of the growth rate
inhibition of combinations of CUR and LUT. The plots of combination index and inhibitory
effects (Fractions of affected cells, Fa) are shown in Figure 1C. The combination (C15L30)
of CUR at 15 µM and LUT at 30 µM with a low combination index of 0.25 and highest
inhibitory effect/Fa value of (0.75) was selected as the optimum combination for further
studies in CL-188 and DLD-1 cells. As shown in Figure 1D,E, the combination C15L30 has
the best inhibitory effect (reduced cell numbers to 51% of DMSO control, p = 0.00012) in
CL-188 cell proliferation, which is significantly lower than the number of the combination
C10L30 (69.6% of DMSO, C10L30 vs. C15L30 p = 0.00043) and individual chemicals C15
(83.6% of DMSO, C15 vs. C15L30, p = 0.0011), C10 (91.4% of DMSO, C10 vs. C10L30,
p = 0.0044), and L30 (92.0% of DMSO, L30 vs. C15L30, p = 0.0036). These results were
also confirmed in other human colon cancer DLD-1 cells (Figure 1F,G) in which C15L30
synergistically inhibited cell proliferation to 31.4% of DMSO, p = 0.00014) compared to
C10L30 (47.6% of DMSO, C10L30 vs. C15L30, p = 0.0056) and individual chemicals C15
(70.0% of DMSO, C15 vs. C15L30, p = 0.00308), C10 (77.3% of DMSO, C10 vs. C10L30,
p = 0.00173, and L30 (84.1% of DMSO, L30 vs. C15L30, p = 0.0016). The reason for selecting
these two cell lines to confirm the inhibitory effect of C15L30 is not selective in only one
cell line, given that these two colon cancer cell lines have same (adenocarcinoma, having
molecules MSI, BRAF, and PTEN) and different (morphology, original patient gender,
molecules CIMP, PIK3CA, and TP53) features [28]. Therefore, the combination C15L30
really synergistically inhibited colon cancer cell proliferation both in CL-188 cells and
DLD-1 cells.
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combination CURLUT was significantly smaller than those in other groups with VEH
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Figure
Combination of
of curcumin
curcumin (CUR)
(LUT)
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induced
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in
Figure
5. 5.Combination
(CUR)and
andluteolin
luteolin
(LUT)
synergistically
induced
necrosis
in
xenograft colon tumors: (A). Representative images of all groups. Areas of necrosis are pink-orange
xenograft colon tumors: (A). Representative images of all groups. Areas of necrosis are pink-orange
(asterisks); Intact tumor areas are dark pink-purple. 20× magnification. (B). A box plot showing
(asterisks); Intact tumor areas are dark pink-purple. 20× magnification. (B). A box plot showing
necrosis of tumors (percentage of total area) within groups. + Significant difference between group
and LUT group. ++ p < 0.01. n = 7–9.
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4. Discussion
This study identified a novel combination of luteolin and curcumin that exerts synergistic anti-colon cancer effects both in vitro and in vivo. However, the individual luteolin
and curcumin have much less or no such effects at the selected concentrations. This synergistic anti-colon cancer effect of the combination of luteolin and curcumin was observed in
two human colon CL-188 cells and DLD-1 cells as well as in CL-188 cells-derived xenograft
mice. Moreover, this synergistic effect of the combination of luteolin and curcumin was also
observed in the protein expressions of Notch1 and TGF-β in CL-188 cells and xenograft
tumors, which is in line with the anti-cancer effect in cells and tumors. We also found
that this combination of luteolin and curcumin significantly induced necrosis in tumors.
Therefore, the combination of luteolin and curcumin synergistically exerts anti-colon cancer
through regulating Notch1 and TGF-β pathways and inducing necrosis.
While phytochemicals have been extensively investigated in colon cancer prevention
and treatment, there is a big gap between effective concentrations of phytochemicals in
cells (µM) and the physiological circulating levels of the phytochemicals in humans (nM),
mainly via dietary supplementation of pure phytochemicals or foods [29]. Our solution
for this significant gap is to combine two phytochemicals at relatively low concentrations
to prevent/treat colon cancer. Therefore, the primary goal of this study is to identify
a combination of two phytochemicals synergistically inhibiting colon cancer while the
individual phytochemical does not have the inhibitory effect at the selected concentration.
As aforementioned, the combination C15L30 is identified and worked in both in vitro
studies and xenograft mice. In addition, we also found that the combination of luteolin
and curcumin synergistically inhibited breast cancer both in cultured cells and xenograft
mice (separate paper), indicating that the combination of luteolin and curcumin may
synergistically inhibit all cancers; although, more studies are needed. Indeed, there are
increasing reports that combined phytochemicals exert synergistic anti-cancer effects. For
instance, Emulsome nanoformulations of curcumin (25 µM) and piperine (7 µM) effectively
suppressed cell proliferation to about 50% viability in colorectal cancer HCT116 cells [30].
Combined curcumin and resveratrol inhibited proliferation in p53 positive and negative
colon cancer HCT-116 cells [31].
Based on the increasing studies, we recently summarized five mechanisms to understand how a combination of two or more phytochemicals exerts synergistic effects in cells,
animals, and humans [32]: (1) enhance the bioavailability of phytochemicals; (2) increase
antioxidant capacity; (3) interact with gut microbiome (change microbial profiles, reduce
endotoxin and increase gut integrity); (4) target same and/or different signaling pathways;
and (5) apply two or more of these four mechanisms simultaneously. For instance, the
combination C15l30 synergistically affected protein levels of Notch1 and TGF-β and the
rate of necrosis in tumors, which are in line with its inhibitory effects in cells and tumors,
indicating that the combination C15L30 may inhibit colon cancer by regulating Notch1 and
TGF-β pathways. In addition, the combination C15L30 not only can inhibit colon cancer
cell proliferation but also synergistically suppress the cancer migration and invasion (by
wound healing assay) as well as necrosis (tumor tissue analysis). Therefore, the combination
C15L30 may prevent/treat colon cancer through multiple approaches and mechanisms.
Our other study found that the combination of LUT and CUR synergistically inhibited
breast cancer both in cultured cells and xenograft mice, which is in line with the results of
the current study, indicating that the synergistic inhibition of the combination of LUT and
CUR may be universal for several different cancers. Particularly, RNA-seq transcriptome
analysis in breast cancer tumors found that Notch1 and TGF-β pathways are the top
two pathways contributing to the synergistic inhibition by the combination of LUT and
CUR, and the protein analysis of Notch1 and TGF-β in tumors matched the RNA changes
(separate manuscript). Therefore, we measured the tumor protein levels of Notch1 and
TGF-β in this study when we found that the combination of LUT and CUR synergistically
inhibited colon cancer both in cultured cells and xenograft mice.
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Several studies have linked the increase in proliferation of colon cancer cells to Notch1
signaling [33,34]; particularly, Notch1 regulates cell proliferative abilities and regulates
apoptosis in cells [35]. Jagged-1, a ligand of Notch1, contributes to metastasis in colon cancer [36]. Therefore, downregulation of the Notch1 signaling pathway may be an excellent
approach to colon cancer therapy. As documented by Wang et al., curcumin has Notch
inhibiting activity that may be used to treat cancer stem cells and solid tumors [37]. Notch1
induced cyclin D1 and CDK2 activity, two key molecules of cell proliferation in cervical
cancer cells [38]. In the current study, we demonstrated that the combination of curcumin
and luteolin down-regulates the protein expression in cultured cells and xenograft tumors.
Therefore, the inhibitory effect in colon cancer by combined curcumin and luteolin is at
least due to Notch1 downregulation.
The disruption of TGF-β could lead to various diseases, including cancer. TGF-β
signaling is highly overexpressed, leading to tumor angiogenesis, invasion, migration,
and metastasis in cancers, including breast cancer [39]. Gold et al. reported curcumin
and emodin down-regulated TGF-β signaling in cervical cancer cells [40]. Evidence suggests that curcumin-induced apoptosis and reversed EMT through the downregulation
of the TGF-β-signaling cascade in pancreatic cancer [41] and breast cancer [42]. In our
wound healing assay, combined curcumin and luteolin synergistically inhibit migration
and invasion in vitro. Immunoblotting of TGF-β in cells and mice tumors showed that
the TGF-β protein expression was downregulated by the combination of curcumin and
luteolin. These results suggest that TGF-β may be responsible for inhibited invasion and
angiogenesis in colon cancer by the combination of curcumin and luteolin in both in vitro
and in vivo studies.
There are several limitations of this study: (1) if knocking out genes of Notch1 and TGFβ abolish the anti-colon cancer effects of the combination of luteolin and curcumin; (2) IP
injection of chemicals is not a typical approach in nutrition research; (3) a comprehensive
study of the molecular mechanisms of the anti-colon cancer effects of the combination
of luteolin and curcumin is required. Therefore, the future studies will be: (1) to knock
out Notch1 and TGF-β genes in cells to test if this knockout can abolish the anti-colon
cancer effects of the combination of luteolin and curcumin; (2) chemicals will be dietarily
supplemented to xenograft or chemically induced colon cancer mice to test the synergistic
anti-colon cancer effects by the combination of luteolin and curcumin; (3) whole-genome
RNA-sequencing and metabolomic analysis of tumors will figure out comprehensive
mechanisms on how combined luteolin and curcumin synergistically inhibit colon cancer.
5. Conclusions
In conclusion, a combination of luteolin (30 µM) and curcumin (15 µM) was selected
as the optimum combination for the study due to a low combination index of 0.25 and its
highest synergistic inhibitory effect on the growth of two human colon cancer cell lines
CL-188 and DLD-1. Consistent with in vitro results, intraperitoneal injection of luteolin at
10 mg/kg body weight and curcumin at 20 mg/kg body weight in BALB/C Foxn nude mice
for a 2-week period synergistically inhibited CL-188 cell-derived tumor growth. Further
analysis showed that the synergistic anti-colon cancer effect exhibited by curcumin and
luteolin was mediated through the downregulation of the effector protein Notch1, to induce
growth cycle arrest, promote apoptosis, and TGF-β signaling inhibits angiogenesis and
invasion in vitro and in vivo. These data demonstrate that a combination of curcumin and
luteolin exerts an anti-colon cancer effect through the modulation of Notch1 and TGF-β
signaling pathways, well-known in cancer growth, invasion, and metastasis. Therefore,
these results provide solid evidence that the consumption of specific foods rich in curcumin
and luteolin may be a practical approach to prevent or treat colon cancer in humans after
more studies.
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Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/cancers14123001/s1, Figure S1: Uncropped western blot images
related to Figure 3A,B. Figure S2: Uncropped western blot images related to Figure 4E,F.
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